Abstract
Background The majority of COVID-19 cases are asymptomatic, or minimally symptomatic with management in the home. Little is known about the frequency of specific symptoms in the general population, and how symptoms predict the magnitude of antibody response to SARS-CoV-2 infection.
Methods We quantified IgG antibodies against the SARS-CoV-2 receptor binding domain (RBD) in home-collected dried blood spot samples from 3,365 adults participating in a community-based seroprevalence study in the city of Chicago, USA, collected between June 24 and November 11, 2020.
Results 17.8% of the sample was seropositive for SARS-CoV-2. A cluster of symptoms (loss of sense of smell or taste, fever, shortness of breath, muscle or body aches, cough, fatigue, diarrhea, headache) was associated with stronger anti-RBD IgG responses among the seropositives. 39.2% of infections were asymptomatic, and 2 or fewer symptoms were reported for 66.7% of infections. Total number of symptoms was positively but weakly associated with IgG response: Median anti-RBD IgG was 0.95 ug/mL for individuals with 3 or more symptoms, in comparison with 0.61 ug/mL for asymptomatic infections.
Conclusion We document high rates of asymptomatic and mild infection in a large community-based cohort, and relatively low levels of anti-SARS-CoV-2 IgG antibody in the general population of previously exposed individuals.
Competing Interest Statement
Dr. McDade reports that he has a financial interest in EnMed Microanalytics, a company that conducts lab tests using DBS samples.
Dr. D’Aquila reports personal fees from Abbvie, outside the submitted work.
Dr. McNally reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from Cytokinetics, personal fees from Pfizer, personal fees from Tenaya Therapeutics, personal fees from 4D Molecular Therapeutics, outside the submitted work.
Funding Statement
This material is based upon work supported by the National Science Foundation under Grant No. 2035114. Additional support was provided by the Northwestern University Office of Research, the Northwestern University Clinical and Translational Sciences Institute (NIH UL1TR001422), and a generous gift from Dr. Andrew Senyei and Noni Senyei. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All samples were de-identified and all research activities were implemented under protocols approved by the institutional review board at Northwestern University (#STU00212457 and #STU00212472).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon request from the corresponding author subject to an approved data sharing agreement to protect participant confidentiality.
